BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21193597)

  • 1. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients.
    Tang L; Zhang XP; Sun YS; Shen L; Li J; Qi LP; Cui Y
    Radiology; 2011 Mar; 258(3):729-38. PubMed ID: 21193597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging.
    Sun YS; Zhang XP; Tang L; Ji JF; Gu J; Cai Y; Zhang XY
    Radiology; 2010 Jan; 254(1):170-8. PubMed ID: 20019139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
    Gong NJ; Wong CS; Chu YC; Gu J
    NMR Biomed; 2013 Feb; 26(2):185-92. PubMed ID: 22806958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
    Shankar S; vanSonnenberg E; Desai J; Dipiro PJ; Van Den Abbeele A; Demetri GD
    Radiology; 2005 Jun; 235(3):892-8. PubMed ID: 15833985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging.
    Kim SY; Lee SS; Byun JH; Park SH; Kim JK; Park B; Kim N; Lee MG
    Radiology; 2010 Jun; 255(3):815-23. PubMed ID: 20501719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging.
    Yabuuchi H; Hatakenaka M; Takayama K; Matsuo Y; Sunami S; Kamitani T; Jinnouchi M; Sakai S; Nakanishi Y; Honda H
    Radiology; 2011 Nov; 261(2):598-604. PubMed ID: 21852569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
    Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
    Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Cohen MH; Farrell A; Justice R; Pazdur R
    Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases.
    Cui Y; Zhang XP; Sun YS; Tang L; Shen L
    Radiology; 2008 Sep; 248(3):894-900. PubMed ID: 18710982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
    Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy.
    Barbaro B; Vitale R; Valentini V; Illuminati S; Vecchio FM; Rizzo G; Gambacorta MA; Coco C; Crucitti A; Persiani R; Sofo L; Bonomo L
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):594-9. PubMed ID: 22099033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors.
    Seshadri RA; Rajendranath R
    J Cancer Res Ther; 2009; 5(4):267-71. PubMed ID: 20160360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
    J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.